@article {NAKAMOTO3109, author = {SHOGO NAKAMOTO and MASAHIKO IKEDA and SHINICHIRO KUBO and MARI YAMAMOTO and TETSUMASA YAMASHITA}, title = {Dynamic Changes in Absolute Lymphocyte Counts During Eribulin Therapy Are Associated With Survival Benefit}, volume = {41}, number = {6}, pages = {3109--3119}, year = {2021}, doi = {10.21873/anticanres.15095}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: We investigated the usefulness of dynamic changes in absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) during eribulin therapy as predictive markers for survival benefit including post-progression survival (PPS). Patients and Methods: We retrospectively investigated 94 advanced breast cancer (ABC) patients who underwent eribulin therapy between July 2011 and June 2020. Results: The multivariate analysis showed that high baseline ALC and low NLR were independent predictive markers for overall survival (OS) (p=0.007 and p=0.011, respectively) and PPS (p=0.005 and p=0.007, respectively). Dynamic changes in ALC were also associated with OS and PPS (p=0.015, and p=0.026, respectively) and were an independent predictive marker for PPS (p=0.021). Conclusion: Baseline ALC and NLR and dynamic changes in ALC during eribulin therapy were significantly associated with survival benefit including PPS for patients with ABC.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/41/6/3109}, eprint = {https://ar.iiarjournals.org/content/41/6/3109.full.pdf}, journal = {Anticancer Research} }